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Abstract
Background: The purpose of this study was to investigate invasion and metastasis related genes in gastric cancer.
Methods: The transwell migration assay was used to select a highly invasive sub-line from minimally invasive
parent gastric cancer cells, and gene expression was compared using a microarray. MMP28 upregulation was
confirmed using qRT-PCR. MMP28 immunohistochemistry was performed in normal and gastric cancer specimens.
Invasiveness and tumor formation of stable cells overexpressing MMP28 were tested in vitro and in vivo.
Results: MMP28 was overexpressed in the highly invasive sub-cell line. Immunohistochemistry revealed MMP28
expression was markedly increased in gastric carcinoma relative to normal epithelia, and was significantly
associated with depth of tumor invasion, lymph node metastasis and poorer overall survival. Ectopic expression of
MMP28 indicated MMP28 promoted tumor cell invasion in vitro and increased gastric carcinoma metastasis in vivo.
Conclusions: This study indicates MMP28 is frequently overexpressed during progression of gastric carcinoma, and
contributes to tumor cell invasion and metastasis. MMP28 may be a novel therapeutic target for prevention and
treatment of metastases in gastric cancer.
Background
Gastric cancer is second only to lung cancer as the lead-
ing cause of cancer-related deaths worldwide [1].
Whereas the overall incidence of gastric cancer has
declined, the incidence remains high in Asian countries
[1,2]. Although the early stages of gastric cancer are cur-
able, most patients are diagnosed with late-stage disease,
which currently has limited successful therapeutic strate-
gies [3]. Surgery and combination chemotherapies confer
only modest survival benefits in advanced gastric cancer,
resulting in an overall 5 year survival rate of <24% [4,5].
Therefore, understanding of the molecular and genetic
factors involved in gastric cancer progression may iden-
tify novel gastric biomarkers and highlight potential ave-
nues of investigation for targeted therapies.
Matrix metalloproteinase 28 (MMP28), also known as
epilysin, is a metalloproteinase cloned originally from
human keratinocytes, testis, and lung cDNA libraries
[6]. In rodents, MMP28 is expressed in many normal
adult tissues, including testis, intestine, skin, and lung,
suggesting a role in tissue homeostasis [7]. Fetal expres-
sion is observed in the brain, kidney and skeletal muscle
[6]. Similarly to other MMPs, MMP28 is overexpressed
in multiple disease states [8]. In some tumors and can-
cer cell lines MMP28 expression is increased [9-11];
although in some cases MMP28 protein is downregu-
lated in cancer compared to normal tissues [12]. In
wounded skin, strong upregulation of MMP28 occurs in
mitotic cells behind the advancing wound edge, but not
in actively migrating keratinocytes which secrete other
MMPs such as collagenase, stromelysin, and gelatinase
[10]. Tumor necrosis factor a (TNFa), but not the ten
other growth factors tested, strongly stimulated MMP28
expression in primary cultures of human keratinocytes
[10]. A conserved region upstream of the MMP28 tran-
scription initiation site contains a putative NFBb i n d -
ing site. MMPs act not only as metalloproteinases, as
the ability of MMPs to regulate cell behavior is becom-
ing increasingly evident [13]. For example, overexpres-
sion of MMP28 in lung adenocarcinoma cells induces
an epithelial-to-mesenchymal transition (EMT) via acti-
vation of latent TGFb [14,15]. MMP28-induced EMT is
associated with loss of E-cadherin, a major mediator of
cell-cell adhesion, as well as increased expression of
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expression of MMP28 is increased in oral squamous cell
carcinoma (OSCC) compared to premalignant lesions
[11]. Knockdown of MMP28 leads to inhibition of
anchorage independent growth in both OSCC (oral
squamous cell carcinomas)and esophageal carcinomas
[11].
The results of this study demonstrate MMP28 is over-
expressed in a highly invasive sub-line of PAMC82 cells.
Immunohistochemical analysis revealed MMP28 is over-
expressed in gastric carcinoma relative to normal epithe-
lial cells, and MMP28 is significantly associated with
depth of tumor invasion, lymph node metastasis and a
poorer overall survival. Our data demonstrates MMP28
is frequently overexpressed during gastric carcinoma
progression and contributes to tumor cell invasion and
metastasis.
Methods
Cell lines and cell culture
Human gastric cancer cell lines PAMC82 [16], N87[17],
BGC823, SNU16, SNU5, SGC7901, MGC803, AGS and
MKN45 were maintained in RPMI 1640 (HyClone,
Logan, UT, USA) supplemented with 10% fetal bovine
serum (Invitrogen, Carlsbad, CA, USA). To select for a
highly invasive subpopulation, PAMC82 cells were
seeded on matrigel (BD Biosciences, Bedford, MA, USA)
in 8 μm pore transwell inserts (Costar, Cambridge, MA,
USA). Cells which invaded through the membrane and
attached to the lower well were harvested and expanded.
Serial selection of cells for increased invasiveness was
continued for three generations, and the sub-lines from
the three different generations were designated as
PAMC82-P1, PAMC82-P2 and PAMC82-P3 respectively.
Microarray
A 22K Human Genome Array, a product of the Human
Genome Oligo Set Version 2.1 (http://www.Operon.
com) was used to compare gene expression profiles in
PAMC82-P3 relative to PAMC82 at the Bioassay
Laboratory, CapitalBio Corporation Beijing, China. Data
on the gene array is provided in supplementary data S1.
Quantitative RT-PCR
Total cellular RNA preparation and reverse transcription
of 4 μg total cellular RNA to cDNA was performed as pre-
viously described [18,19], and cDNA was diluted 1:10 and
used for PCR. Using the published cDNA sequence (Gen-
Bank Accession no. AF219624) primers were designed to
amplify a 258-bp product of human MMP-28 (forward: 5’-
CTCATCCTCTTCAAGGGTG-3’, nt 1,366 to 1,383 and
reverse: 5’-GGAAGAAGATGATGGAGCCA-3’,n t1 , 6 0 6
to 1,623). The U6 gene was used as an endogenous control
(forward 5’-GCTTCGGCAGCACATATACTAAAAT-3’
and reverse 5’-CGCTTCACGAATTTGCGTGTCAT-3’)
amplifying a 89 bp product. Primers and probes were
obtained from Applied Biosystems (Carlsbad, CA, USA)
and qRT-PCR was performed as previously described [20].
Immunohistochemical staining of gastric carcinoma tissue
MMP28 expression was determined by immunohisto-
chemistry in 304 clinical cases of gastric cancer, of which
clinical follow-up data was available for 274 patients. In
addition, 30 of these specimens had paired normal gastric
epithelia and another 30 had paired lymph node metasta-
sis. Immunostaining was performed using the CSA kit
(DAKO, Glostrup, Denmark) with a 1 h incubation of an
anti-MMP28 antibody (M5066, 2 μg/ml, Sigma, St. Louis,
MO, USA) in citrate buffer. Slides were evaluated by two
pathologists and MMP28 expression was semi-quantita-
tively scored based on the staining intensity and percen-
tage of cells stained. Tissues with no staining were scored
as 0, faint staining, moderate or strong staining in <25%
of cells scored as 1, moderate staining or strong staining
in 25-50% cells scored as 2 and strong staining in >50%
cells was scored 3.
MMP28 overexpressing N87 cells
PCR primers incorporating BamHI( 5 ’)a n dXhoI( 3 ’)
(restriction sites underlined; forward 5’-CGCGGATCCGC
CGCCGCCATGGTCGCGCGCGTCGGCCTC-3’ and
reverse 5’-ACGTCTCGAGCCGAACAGGGCGCTCCCC-
GAGTTG-3’) were designed to amplify and clone human
MMP28 into the pcDNA3.1 expression vector (Invitrogen)
containing a C-terminus His-6 epitope to produce
the pcDNA3.1-MMP28-c-His vector. Sequencing of
the cloned gene was performed in both directions. The
pcDNA3.1-MMP28-c-His vector was transfected into the
gastric cancer cell line N87 and stable cell lines were
selected by incubation with 500 μg/ml G418 for 2 weeks.
Western blot analysis
Proteins were separated by sodium dodecylsulphate-
polyacrylamide gel (SDS-PAGE) electrophoresis, trans-
ferred to polyvinylidene difluoride membranes (PVDF;
Millipore, Bedford, MA, USA), blocked and then probed
with anti-MMP28 (0.2 μg / m l ,M 5 0 6 6 ,S i g m a ,S t .L o u i s ,
MO, USA) and ß-actin (1:5,000, Sigma) antibodies.
After washing, the blots were incubated with horserad-
ish peroxidase-conjugated secondary antibodies and
visualized using an enhanced chemiluminescence kit
(Pierce, Rockford, IL, USA).
Matrigel chemoinvasion assay
T h em a t r i g e lc h e m o i n v a s i o na s s a yw a sp e r f o r m e da s
previously described, with some modifications. Briefly,
4×1 0
4 cells were seeded onto 6.5 mm Costar transwells
(Corning, Lowell, MA, USA) coated with 150 μg/ml
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remained inside the insert were removed with a cotton
swab and cells which had invaded to the lower surface
of the membrane were fixed in 50:50 methanol: acetone
and stained with 4,6-diamidino-2-phenylindole (DAPI).
After air drying the membrane, the number of cells in
three random x100 fields was counted using a fluores-
cence microscope. Experiments were performed in tri-
plicate and repeated twice; therefore, the values
represent the mean number of invasive cells in 18 × 100
fields of view. Differences in value distribution were ana-
lyzed using one-way ANOVA, p < 0.05 was considered
significant.
Xenograft assays in nude mice
Nu/nu mice were obtained from the Jackson Laboratory
(Vital River, Beijing, China) and maintained in a specific
pathogen-free facility at the Experimental Center of the
Chinese Academy of Medical Science, which is accre-
dited by the Chinese Association for Accreditation of
Laboratory Animal Care. For the spontaneous metastasis
assay, stable MMP28 over-expressing N87 cells (N87-C9
and N87-C10) or control cells (N87-Ve) were subcuta-
neously injected into female 4-wk-old mice. The mice
were euthanized 9 weeks after injection and examined
for subcutaneous tumor growth and development of
metastases.
Statistical analysis
Invasion assay results were compared using One-way
ANOVA. Statistical analyses of MMP28 expression and
clinicopathological data was performed using Fisher’s
exact test. For survival analysis, Kaplan-Meier survival
curves were constructed and tested by the log-rank test,
p < 0.05 were considered statistically significant.
Results
MMP28 is overexpressed in the highly invasive PAMC82-
P3 sub-line
The highly invasive cancer cell line PAMC82-P3 was
selected from the parental PAMC82 cell line by multiple
rounds of invasion thorough matrigel. The ability of
PAMC82-P3 to invade matrigel was 8-fold greater than
parental PAMC82 cells, but not significantly different to
the second-generation line PAMC82-P2 (Figure 1A),
suggesting that invasive potential reached a plateau after
two rounds of selection. The expression profiles of
PAMC82 and PAMC82-P3 cells were analyzed using the
22K Human Genome Array microarray (Human Gen-
ome Oligo Set Version 2.1). 289 genes were differentially
expressed by a factor of 2-fold or more, of which 213
were upregulated and 76 were downregulated in
PAMC82-P3 relative to PAMC82 (Additional file 1).
Most of the differentially expressed genes have been
previously shown to be involved in tumor invasion and
Figure 1 MMP28 expression correlates with the invasive ability of gastric carcinoma cell lines. (A) PAMC82 sub-lines with low and high
invasive abilities were established and tested using the transwell invasion assay. P1-P3 cells indicated increased invasive ability, with no
difference observed between P2 and P3 cells. (B) qRT-PCR analysis of MMP28 in PAMC82, P1 and P3 cells indicating MMP28 expression correlates
with invasive ability. (C) MMP28 expression correlates with invasive ability in a range of gastric carcinoma cell lines. Top: transwell invasion assays
of nine gastric cancer cell lines. Bottom: Western blot analysis of activated and total MMP28.
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LOXL2 [22], cadherin 16 [23], lectin galactoside-binding
soluble protein1 [24], thymidine phosphorylase [25] and
LY6/PLAUR domain containing 3 [26]. One of the dif-
ferentially expressed genes, MMP28, was of particular
interest and qRT-PCR analysis revealed MMP28 expres-
sion was gradually upregulated from the parental
PAMC82 cells to the highly invasive PAMC82-P3 cells
(Figure 1B, Additional file 2). In order to confirm this
finding, MMP28 protein expression and invasive poten-
tial was examined in a range of human gastric cancer
cell lines. We found that MMP28 expression was posi-
tively correlated with the invasive ability of the cells
(Figure 1C).
MMP28 is overexpressed in gastric carcinoma and
correlates with poorer survival
We evaluated the expression of MMP28 in 30 paired cases
of gastric carcinoma tissue and normal epithelium. Com-
pared to normal tissues, MMP28 was overexpressed in
43.3% (13/30) of the primary tumors (Figure 2A, > level
2). MMP28 was mostly localized to cytoplasm and extra
cellular stroma, and this expression pattern was confirmed
using fluorescent staining of N87-C9 cells transfected with
MMP28 (Data not shown). MMP28 was significantly over-
expressed in both primary tumors (2.08 ± 0.71) and lymph
node metastatic foci (2.36 ± 0.89), compared to normal tis-
sues (0.94 ± 0.68, Mean ± SD, semi-quantitative scores,
p < 0.01, Figure 2B). The prognostic significance of
MMP28 was assessed in 274 cases of gastric cancer with
clinical follow-up records. Increased MMP28 expression
in gastric carcinoma was correlated with depth of tumor
invasion (p < 0.0001) and lymph node metastasis (p <
0.0001, Table 1). There was no significant association with
MMP28 and patient age, sex or tumor differentiation.
Kaplan-Meier survival analysis of 152 gastric carcinoma
specimens revealed a significantly shorter overall survival
times in tumors with higher MMP28 expression (p < 0.01,
Figure 2C). Furthermore, multivariate analysis revealed
that MMP28 was an independent prognostic factor in gas-
tric cancer (Table 2).
MMP28 overexpression increases the invasive ability of
gastric cancer cells
To examine the functional consequence of elevated
MMP28 expression in gastric cancer cells, His-tagged
MMP28 was overexpressed in N87 gastric cancer cells,
which exhibit a low endogenous level of MMP28
(Figure 3A). In the matrigel invasion assay, invasion
significantly increased in two stable MMP28 overex-
pressing N87 cell sub-lines (MMP28-C9: 60.8 ± 12.17;
MMP28-C10: 68 ± 7.94) compared to transfected con-
trol and control cells (N87-Pa: 11 ± 2.09; N87-Nc: 11.8
± 3.19 respectively (p < 0.01, Figure 3B).
MMP28 promotes growth and spontaneous metastasis of
gastric cancers in vivo
To define the function of MMP28 in vivo,w es u b c u t a -
neously injected MMP28-overexpressing N87 clones
(N87-C9 and C10) into athymic mice, and mice were
euthanized 9 weeks later. MMP28 significantly promoted
growth of N87 xenografts (MMP28-C9: 4.32 ± 2.45 cm
3;
MMP28-C10: 4.45 ± 1.38 cm
3) compared to transfected
control (N87-Pa: 2.87 ± 1.45 cm
3) or control N87 cells
(N87-Ve: 2.99 ± 1.24 cm
3, p < 0.05 Figure 3C). Expression
of MMP28 increased volume and weight of tumors, so the
proliferation rate of the MMP-28 overexpressing clones
Figure 2 Overexpression of MMP28 protein in gastric cancer is
correlated with tumor aggressiveness and poorer prognosis.
(A) Representative images of immunohistochemical staining
showing MMP28 is overexpressed in gastric cancer compared to
normal tissues. (B) Semi-quantitative immunohistochemical analysis
indicating MMP28 is significantly overexpressed in primary gastric
carcinomas (2.08 ± 0.71) and lymph node metastases (2.36 ± 0.89)
compared to normal tissues (0.94 ± 0.68, p < 0.01) in 30 paired
samples. (C) Kaplan-Meier survival curves showing significantly
reduced survival in subjects with high MMP28 expression (p < 0.01,
log-rank test). Positive primary gastric cancer tissues were those
classified as MMP28 moderate to strong (expression score of 2 and
3).
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cantly different to control cells (data not shown). Ki67
expression in all xenograft tumors groups was similar
(Figure 3D). As MMP28 increased invasion and tumor
volume in the absence of altered proliferation, we
hypothesize MMP28 may influence expression of other
genes related to tumor growth or vascular formation.
MMP28 over expressing N87 (N87-MMP28) xenograft
t u m o r ss h o w e dah i g h l yi n v a s i v ep a t t e r ni nH Es t a i n i n g
sections (Figure 3D), indicating MMP28 expression signifi-
cantly promotes xenograft tumor invasion into the sur-
rounding tissue. MMP28 overexpression also significantly
promoted the spontaneous metastasis of N87 cells to lung.
The lungs of mice in the N87-MMP28 group had evident
metastatic nodules, whereas these were barely visible on
the lung surface of the control cohort (Figure 3D). H&E
staining revealed a significant increase in lung metastases
in MMP overexpressing N87 injected mice (MMP28-C9:
14.3 ± 3.43 and MMP28-C10: 15.6 ± 4.34) compared to
mice injected with control cells (N87-Pa: 3.0 ± 0.64 and
N87-Ve: 2.0 ± 0.43, p < 0.01 Figure 3D,E).
Discussion
Metastasis is a multifactorial process, requiring escape of
the normal microenvironment by tumor cells, entrance in
and out of lymphatic or blood vessels and proliferation in
distant tissue microenvironments [27]. Implicit in these
stages of metastasis is the critical ability of tumor cells to
invade [27]. During invasion, malignant cells reside within
two major types of extracellular matrix: the basement
membrane or the stromal matrix [28]. Basement mem-
brane is one of the most important barriers against cancer
cell invasion [28]. Therefore, for this study, we used BD
Matrigel, a solubilized basement membrane preparation,
isolated from the Engelbreth-Holm-Swarm mouse sar-
coma, to model mimic gastric carcinoma invasion in vivo.
Using a transwell chamber, we isolated the highly invasive
subpopulation PAMC82-P3 from the parental PAMC82
cell line. In vitro selection provides a useful approach to
isolate cell sub-lines with different invasion and metastatic
potentials. Microarray analysis was used to determine the
g e n e sw h i c hm a yb ei n v o l v e di ni n v a s i o n ,a n dMMP28
was one of the most interesting genes shown to be differ-
entially regulated in PAMC82-P3 cells compared to
PAMC cells.
MMP28 (epilysin), structurally belongs to the MMP19
subfamily, and represents one of the newest MMP
member. MMP28 is expressed in normal and carcinoma
tissues [29], basal keratinocytes at and surrounding
wound edges [30], in fetal tissues and rhesus monkey
placenta during early pregnancy [31], suggesting a role
for MMP28 in normal tissue homeostasis, wound repair,
and development, as well as in tumor progression
[11,14]. MMP28 may also be involved in immune func-
tion, as it is expressed in normal circulating human T
lymphocytes and is upregulated in osteoarthritic carti-
lage [32]. Few studies have investigated expression of
MMP28 in human tumor samples; however, it is overex-
pressed in oral squamous cell carcinoma [11]. This
study demonstrates MMP28 protein is overexpressed in
gastric tumors (30/30, 100%) compared to normal
epithelia (16/30, 53.3%, p < 0.001). MMP28 protein was
expressed in gastric cancer cells and lymph node metas-
tasis and not located in the surrounding normal tissues.
This study also indicates MMP28 expression is signifi-
cantly positively correlated with tumor invasion, lymph
node metastasis and tumor-node-metastasis stage (p <
0.001), suggesting MMP28 plays a role in gastric carci-
noma invasion and metastasis. Taken together, these
data indicate MMP28 plays an important role in gastric
cancer progression.
Illman SA et al. demonstrated expression of MMP28
altered cell phenotype towards a more adhesive, less
migratory behavior [14]. However, biological evidence
from in vitro and in vivo experiments has not yet
Table 1 Association of MMP28 protein expression with




Variable 0 1 2 3 P value
Age(yrs) Mean 67.0 60.8 63.7 61.0 0.374
SD 11.0 12.8 11.9 14.3
Gender Male 29 66 70 20 0.l94
Female 7 17 24 14
pT1 9 11 5 1 <0.0001*
pT (primary tumor) pT2 21 49 28 8
pT3 11 25 50 17
pT4 9 8 14 8
pN0 28 19 6 1 <0.0001*
pN (lymph node
metastasis)
pN1 13 43 26 4
p N 2 9 2 74 51 2
pN3 0 4 20 17
pM (distant metastasis) pM0 49 87 94 30 0.154
p M 11634
Table 2 Cox multivariate analysis of MMP28 expression
and clinico-pathological features in gastric cancer
Variables Risk ratio (95% CI) P value
pT (primary tumor) 0.693 (0.493-0.974) 0.035*
pN (lymph node metastasis) 1.254 (0.978-1.608) 0.044*
pM (distant metastasis) 0.717 (0.349-1.470) 0.363
Score of MMP28 expression 1.554 (1.119-2.159) 0.008*
*Statistical analysis was performed by a c2 test, p values less than 0.05 were
considered to be statistically significant.
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Page 5 of 8Figure 3 MMP28 positively regulates tumor cell invasion and metastasis. (A) Western Blot of MMP in parental (Pa), transfected control
(N87-Ve) and MMP overexpressing (N87-C9 and N87-C10) N87 stable sub-lines. (B) Number of invasive cells in transwell invasion assays was
significantly different in parental (Pa: 11.8 ± 3.19) and transfected control cells (N87-Ve: 11 ± 2.09) compared to MMP overexpressing stable N87
sub-lines (N87-C9: 60.8 ± 12.17; N87-C10: 68 ± 7.94, mean ± standard error, **p < 0.01). (B) Growth curve (n = 6) of parental (N87-Pa2: 87 ± 1.45
cm
3), transfected control (N87-Ve: 2.99 ± 1.24 cm
3) and MMP overexpressing N87 stable sub-lines (N87-C9: 4.32 ± 2.45 cm
3; N87-C10: 4.45 ± 1.38
cm
3, p < 0.05). (C) Top: H&E staining showing increased xenograft tumor invasion into surrounding tissue in MMP28 overexpressing cells (N87-
C9) compared to control transfected cells (N87-ve), arrows indicate area of muscular invasion. Centre: lung metastasis in control transfected (N87-
ve) and MMP28 overexpressing xenografts (N87-C9) 9 weeks after subcutaneous injection. Bottom: hematoxylin and eosin (HE) staining showing
increased MMP28 expression, and no significant difference in Ki67 cell proliferation, in MMP28 overexpressing xenografts (N87-C9) compared to
control transfected xenografts (N87-ve). (E) Characteristics of control and MMP overexpressing MMP28 tumor xenografts.
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metastasis. In the current study we have shown, to our
knowledge for the first time, that MMP28 positively reg-
ulates invasion of gastric cancer cells in vitro and can
induce a metastatic phenotype in vivo. Increased expres-
sion of MMP28 led to a dose-dependent increase in
invasive ability of N87 cells. These results provide the
first evidence that MMP28 plays an important role in
tumor invasion and metastasis and suggest MMP28 may
be an effective target for suppression of metastasis in
gastric cancer.
Conclusions
We have established a gastric carcinoma invasion model
using a highly invasive sub-line of tumor cells in which
MMP28 was overexpressed. Further investigation
revealed MMP28 is significantly correlated with invasive
and metastatic ability and is a valuable marker of poor
prognosis in gastric cancer. This study provides the first
evidence that MMP28 can promote invasion and metas-
tasis in gastric cancer.
Additional material
Additional file 1: Gene Array of PAMC82-P3 and PAMC82.
Additional file 2: Q-RT-PCR analysis the expression of MMP28.
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